| Title |
A pharmacokinetic drug-drug interaction study between pregabalin and tramadol in healthy volunteers
|
|---|---|
| Published in |
European Journal of Clinical Pharmacology, August 2018
|
| DOI | 10.1007/s00228-018-2543-0 |
| Pubmed ID | |
| Authors |
Soyoung Lee, Yun Kim, Janice Ji Sung Lee, Guangjin Im, Joo-Youn Cho, Jae-Yong Chung, Seonghae Yoon |
| Abstract |
Combination therapy of pregabalin and tramadol is used to treat chronic neuropathic pain; however, the pharmacokinetic (PK) interactions of these drugs has not been studied. This study aimed to evaluate PK interactions between pregabalin and tramadol and the safety of combination therapy. A randomized, open-label, multiple-dose, three-treatment, three-period, six-sequence cross-over study was conducted in healthy subjects. All subjects received the following three treatments for 4 days in each period: pregabalin 150 mg twice daily; tramadol extended-release (ER) 200 mg in the morning, and 100 mg in the evening; and co-administration of pregabalin 150 mg and tramadol ER 200 mg in the morning, and pregabalin 150 mg and tramadol ER 100 mg in the evening. A total of 21 subjects completed the study with no clinically significant safety issues. For pregabalin, the geometric mean ratio (GMR) (90% CI; confidence interval) of combination therapy to monotherapy for maximum concentration at steady state (Cmax,ss) and area under the concentration curve from 0 to dosing interval time at steady state (AUCτ,ss) were 0.8801 (0.8043-0.9632) and 1.0830 (1.0569-1.1098), respectively. The corresponding values for tramadol were 1.0177 (0.9839-1.0526) and 1.0152 (0.9896-1.0414), respectively. The GMR (90% CI) of combination therapy to monotherapy of O-desmethyl-tramadol for Cmax,ss and AUCτ,ss was 1.0465 (1.0095-1.0848) and 1.0361 (1.0001-1.0734), respectively. There were no significant drug interactions between pregabalin and tramadol, considering that all of the 90% CI of PK measures were within the conventional bioequivalence range. Both drugs were well tolerated when administered concomitantly. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 33% |
| Japan | 1 | 17% |
| France | 1 | 17% |
| Unknown | 2 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 50% |
| Practitioners (doctors, other healthcare professionals) | 2 | 33% |
| Scientists | 1 | 17% |
Mendeley readers
The data shown below were compiled from readership statistics for 33 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 33 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 7 | 21% |
| Student > Master | 4 | 12% |
| Student > Doctoral Student | 3 | 9% |
| Student > Bachelor | 3 | 9% |
| Student > Postgraduate | 2 | 6% |
| Other | 4 | 12% |
| Unknown | 10 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 36% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 24% |
| Biochemistry, Genetics and Molecular Biology | 1 | 3% |
| Engineering | 1 | 3% |
| Unknown | 11 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 March 2019.
All research outputs
#7,517,664
of 23,100,534 outputs
Outputs from European Journal of Clinical Pharmacology
#837
of 2,574 outputs
Outputs of similar age
#130,136
of 334,082 outputs
Outputs of similar age from European Journal of Clinical Pharmacology
#8
of 27 outputs
Altmetric has tracked 23,100,534 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 2,574 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one has gotten more attention than average, scoring higher than 67% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 334,082 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.
We're also able to compare this research output to 27 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.